- Home
- MAZE
as 03-28-2025 4:00pm EST
Stocks
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 523.1M | IPO Year: | 2025 |
| Target Price: | $25.67 | AVG Volume (30 days): | 260.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.88 - $17.00 | Next Earning Date: | 01-01-0001 |
| Revenue: | $167,500,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest MAZE THERAPEUTICS INC News
MAZE Breaking Stock News: Dive into MAZE Ticker-Specific Updates for Smart Investing
Investing.com
a month ago
Maze Therapeutics receives positive ratings following recent IPO
Clinical Trials Arena
2 months ago
Maze Therapeutics doses first subject in Phase II AKD treatment trial
GlobeNewswire
2 months ago
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
MT Newswires
2 months ago
Maze Therapeutics Prices Upsized IPO at $16 Per Share
Bloomberg
2 months ago
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs
GlobeNewswire
2 months ago
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering
BioPharma Dive
2 months ago
Metsera, Maze secure combined $415 million in IPOs
Compare MAZE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MAZE MAZE THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.